Manipulation of BCG vaccine: a double-edged sword.
(2016) In European Journal of Clinical Microbiology and Infectious Diseases 35(4). p.535-543- Abstract
- Mycobacterium bovis Bacillus Calmette-Guérin (BCG), an attenuated vaccine derived from M. bovis, is the only licensed vaccine against tuberculosis (TB). Despite its protection against TB in children, the protective efficacy in pulmonary TB is variable in adolescents and adults. In spite of the current knowledge of molecular biology, immunology and cell biology, infectious diseases such as TB and HIV/AIDS are still challenges for the scientific community. Genetic manipulation facilitates the construction of recombinant BCG (rBCG) vaccine that can be used as a highly immunogenic vaccine against TB with an improved safety profile, but, still, the manipulation of BCG vaccine to improve efficacy should be carefully considered, as it can bring... (More)
- Mycobacterium bovis Bacillus Calmette-Guérin (BCG), an attenuated vaccine derived from M. bovis, is the only licensed vaccine against tuberculosis (TB). Despite its protection against TB in children, the protective efficacy in pulmonary TB is variable in adolescents and adults. In spite of the current knowledge of molecular biology, immunology and cell biology, infectious diseases such as TB and HIV/AIDS are still challenges for the scientific community. Genetic manipulation facilitates the construction of recombinant BCG (rBCG) vaccine that can be used as a highly immunogenic vaccine against TB with an improved safety profile, but, still, the manipulation of BCG vaccine to improve efficacy should be carefully considered, as it can bring in both favourable and unfavourable effects. The purpose of this review is not to comprehensively review the interaction between microorganisms and host cells in order to use rBCG expressing M. tuberculosis (Mtb) immunodominant antigens that are available in the public domain, but, rather, to also discuss the limitations of rBCG vaccine, expressing heterologous antigens, during manipulation that pave the way for a promising new vaccine approach. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8573693
- author
- Singh, Vipul LU ; Srivastava, R and Srivastava, B S
- organization
- publishing date
- 2016-01-25
- type
- Contribution to journal
- publication status
- published
- subject
- in
- European Journal of Clinical Microbiology and Infectious Diseases
- volume
- 35
- issue
- 4
- pages
- 535 - 543
- publisher
- Springer
- external identifiers
-
- pmid:26810060
- scopus:84955279310
- wos:000373300000003
- pmid:26810060
- ISSN
- 1435-4373
- DOI
- 10.1007/s10096-016-2579-y
- language
- English
- LU publication?
- yes
- id
- 82f278ad-0486-4866-a2c0-42d6844ba887 (old id 8573693)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26810060?dopt=Abstract
- date added to LUP
- 2016-04-04 09:35:16
- date last changed
- 2025-04-04 14:07:42
@article{82f278ad-0486-4866-a2c0-42d6844ba887,
abstract = {{Mycobacterium bovis Bacillus Calmette-Guérin (BCG), an attenuated vaccine derived from M. bovis, is the only licensed vaccine against tuberculosis (TB). Despite its protection against TB in children, the protective efficacy in pulmonary TB is variable in adolescents and adults. In spite of the current knowledge of molecular biology, immunology and cell biology, infectious diseases such as TB and HIV/AIDS are still challenges for the scientific community. Genetic manipulation facilitates the construction of recombinant BCG (rBCG) vaccine that can be used as a highly immunogenic vaccine against TB with an improved safety profile, but, still, the manipulation of BCG vaccine to improve efficacy should be carefully considered, as it can bring in both favourable and unfavourable effects. The purpose of this review is not to comprehensively review the interaction between microorganisms and host cells in order to use rBCG expressing M. tuberculosis (Mtb) immunodominant antigens that are available in the public domain, but, rather, to also discuss the limitations of rBCG vaccine, expressing heterologous antigens, during manipulation that pave the way for a promising new vaccine approach.}},
author = {{Singh, Vipul and Srivastava, R and Srivastava, B S}},
issn = {{1435-4373}},
language = {{eng}},
month = {{01}},
number = {{4}},
pages = {{535--543}},
publisher = {{Springer}},
series = {{European Journal of Clinical Microbiology and Infectious Diseases}},
title = {{Manipulation of BCG vaccine: a double-edged sword.}},
url = {{http://dx.doi.org/10.1007/s10096-016-2579-y}},
doi = {{10.1007/s10096-016-2579-y}},
volume = {{35}},
year = {{2016}},
}